Research ArticleCommentary
Perspectives from the IQ Induction Working Group on Factors Impacting Clinical DDI Due to Induction: Focus on CYP3A Substrates
Diane Ramsden, Conrad Fung, Niresh Hariparsad, Jane R Kenny, Michael A Mohutsky, Neil Parrott, Sarah Robertson and Donald J. Tweedie
Drug Metabolism and Disposition August 22, 2019, dmd.119.087270; DOI: https://doi.org/10.1124/dmd.119.087270
Diane Ramsden
1 Alnylam;
Conrad Fung
2 Vertex Pharmaceuticals;
Niresh Hariparsad
2 Vertex Pharmaceuticals;
Jane R Kenny
3 Genentech Inc;
Michael A Mohutsky
4 Eli Lilly and Company;
Neil Parrott
5 Roche;
Sarah Robertson
2 Vertex Pharmaceuticals;
Donald J. Tweedie
6 Merck Research Laboratories
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleCommentary
Perspectives from the IQ Induction Working Group on Factors Impacting Clinical DDI Due to Induction: Focus on CYP3A Substrates
Diane Ramsden, Conrad Fung, Niresh Hariparsad, Jane R Kenny, Michael A Mohutsky, Neil Parrott, Sarah Robertson and Donald J. Tweedie
Drug Metabolism and Disposition August 22, 2019, dmd.119.087270; DOI: https://doi.org/10.1124/dmd.119.087270
Research ArticleCommentary
Perspectives from the IQ Induction Working Group on Factors Impacting Clinical DDI Due to Induction: Focus on CYP3A Substrates
Diane Ramsden, Conrad Fung, Niresh Hariparsad, Jane R Kenny, Michael A Mohutsky, Neil Parrott, Sarah Robertson and Donald J. Tweedie
Drug Metabolism and Disposition August 22, 2019, dmd.119.087270; DOI: https://doi.org/10.1124/dmd.119.087270
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement